Tide Pharmaceutical Forecasts Up to 32% Revenue Growth for 2025

Tide Projects Revenue Growth Up to 32.3% for 2025

On February 26, Tide Pharmaceutical disclosed its financial outlook for the fiscal year ending December 31, 2025, projecting significant top-line expansion. In a filing with the Hong Kong Stock Exchange, the company guided for annual revenue to land between ¥555 million and ¥585 million. This range represents a substantial year-over-year increase of approximately 25.5% to 32.3%, indicating strong commercial momentum and demand for its products.

Adjusted Profit to Grow by as much as 33.7%

Alongside its optimistic revenue forecast, Tide Pharmaceutical anticipates a considerable rise in profitability. The company projects its adjusted net profit, a non-IFRS measure, to fall between ¥200 million and ¥230 million for 2025. This forecast implies a year-over-year growth rate of 16.3% to 33.7%. The strong guidance on both revenue and profit underscores efficient operational performance and a favorable outlook for shareholder returns, likely to attract positive attention from investors.